The expression of IL-17, in chronic spontaneous urticaria is linked to Semaphorin5A

Matanis, Lobna; Eiza, Nasren; Sabag, Adi; Bejar, Jacob; Giménez Arnau, Anna Maria; Maurer, Marcus; Vadasz, Zahava

doi:http://dx.doi.org/10.3390/biom11030373

The expression of IL-17, in chronic spontaneous urticaria is linked to Semaphorin5A

License

Citation

Matanis L, Eiza N, Sabag A, Bejar J, Giménez-Arnau AM, Maurer M, Vadasz Z. The expression of IL-17, in chronic spontaneous urticaria is linked to Semaphorin5A. Biomolecules. 2021;11(3):373. DOI: 10.3390/biom11030373

Abstract

Background: Patients with chronic spontaneous urticaria (CSU), an autoimmune disorder, show increased skin expression of IL-17A and can benefit from treatment with the anti-IL-17A biologic secukinumab. The mechanisms that drive IL-17A expression in CSU are currently unknown, but may involve Semaphorin5A (Sema5A). Objective: To explore the expression, role, and effects of Sema5A in CSU and its link to IL-17A. Material and Methods: We investigated patients with CSU and healthy controls for skin expression of expressing peripheral T cells. Results: Sema5A was highly expressed in the skin of CSU patients as compared to healthy control skin. Both CD4+ T cells and mast cells in CSU skin expressed Sema5A, and many of them expressed both Sema5A and IL-17A. Patients with CSU had significantly higher rates of IL-17A-expressing CD4+ T cells as compared to healthy controls. Incubation with Sema5A increased the rates of IL-17A-expressing CD4+ T cells in healthy controls to CSU levels. Conclusion: Sema5A may drive the expression and effects of IL-17A in CSU. Further studies in larger cohorts are needed to confirm the role of Sema5A in the pathogenesis of CSU and to explore its potential as a therapeutic target.